Skip to main content

Advertisement

SpringerLink
Log in

Cancer drugs to treat birth defects

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

Identical mutations of the same genes can lead either to congenital malformations or to cancer, depending on their cellular and temporal context. The demonstration of activated RAS-ERK signaling in a mouse model of Apert syndrome suggests that drugs designed to inhibit this pathway in cancer may also delay the progression of several serious pediatric syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: FGFR2 activation and the RAS-ERK pathway.

Katie Ris-Vicari

References

  1. Shukla, V., Coumoul, X., Wang, R.H., Kim, H.-S. & Deng, C.-X. Nat. Genet. 39, 1145–1150 (2007).

    Article  CAS  Google Scholar 

  2. Wilkie, A.O.M. et al. Nat. Genet. 9, 165–172 (1995).

    Article  CAS  Google Scholar 

  3. Ibrahimi, O.A. et al. Hum. Mol. Genet. 13, 2313–2324 (2004).

    Article  CAS  Google Scholar 

  4. Pollock, P.M. et al. Oncogene advance online publication 21 May 2007 (doi: 10.1038/sj.onc.1210529).

    Article  CAS  Google Scholar 

  5. Chen, L., Li, D., Li, C., Engel, A. & Deng, C-X. Bone 33, 169–178 (2003).

    Article  CAS  Google Scholar 

  6. Wang, Y. et al. Development 132, 3537–3548 (2005).

    Article  CAS  Google Scholar 

  7. Kim, D.H. & Rossi, J.J. Nat. Rev. Genet. 8, 173–184 (2007).

    Article  CAS  Google Scholar 

  8. Dailey, L., Ambrosetti, D., Mansukhani, A. & Basilico, C. Cytokine Growth Factor Rev. 16, 233–247 (2005).

    Article  CAS  Google Scholar 

  9. Wilkie, A.O.M. Cytokine Growth Factor Rev. 16, 187–203 (2005).

    Article  CAS  Google Scholar 

  10. Eswarakumar, V.P. et al. Proc. Natl. Acad. Sci. USA 103, 18603–18608 (2006).

    Article  CAS  Google Scholar 

  11. Perlyn, C.A., Morriss-Kay, G., Darvann, T., Tenenbaum, M. & Ornitz, D.M. Neurosurgery 59, 210–215 (2006).

    Article  Google Scholar 

  12. Ohren, J.F. et al. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004).

    Article  CAS  Google Scholar 

  13. Kohno, M. & Pouyssegur, J. Ann. Med. 38, 200–211 (2006).

    Article  CAS  Google Scholar 

  14. Schubbert, S., Shannon, K. & Bollag, G. Nat. Rev. Cancer 7, 295–308 (2007).

    Article  CAS  Google Scholar 

  15. Solit, D.B. et al. Nature 439, 358–362 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Andrew O.M. Wilkie is at the Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. awilkie@hammer.imm.ox.ac.uk,

    Andrew O M Wilkie

Authors
  1. Andrew O M Wilkie
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilkie, A. Cancer drugs to treat birth defects. Nat Genet 39, 1057–1059 (2007). https://doi.org/10.1038/ng0907-1057

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0907-1057

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation